Despite the losses, Kodiak ended 2025 with $209.9 million in cash and cash equivalents, positioning the company well for its ongoing and planned operations into 2027. The company also completed an equity offering in December 2025, raising $173 million by issuing 8 million shares at $23.00 per share.
A key highlight from the report was the positive topline results from the Phase 3 GLOW2 study of Zenkuda (tarcocimab tedromer) in diabetic retinopathy, which demonstrated a significant efficacy and safety profile. The study showed that 62.5% of patients treated with Zenkuda achieved at least a 2-step improvement in diabetic retinopathy severity score compared to just 3.3% in the sham group. This data supports Kodiak's strategy to accelerate the Biologics License Application (BLA) submission for Zenkuda, which is expected to be a major milestone for the company.
In addition to Zenkuda, Kodiak is advancing its pipeline with KSI-101 and KSI-501, both of which are in late-stage clinical trials. The company has completed enrollment in the Phase 3 DAYBREAK study for KSI-501, with topline data expected in September 2026. Kodiak's leadership, including CEO Victor Perlroth, emphasized the company's commitment to developing innovative therapies for retinal diseases and leveraging its proprietary ABC platform to enhance treatment options for patients.
Overall, Kodiak Sciences is positioned for growth with a strong pipeline and financial backing, making it a company to watch in the biotechnology sector.
